ReviewEye and brain2018
Retinal imaging with optical coherence tomography: a biomarker in multiple sclerosis?
Review in Eye and brain, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 91 citations in OpenAlex.
- Swept source optical coherence tomography to early detect multiple sclerosis disease. The use of machine learning techniques.PloS one · 2019Trial
- Optical Coherence Tomography Angiography Findings in Primary Progressive Multiple Sclerosis Patients Receiving Ocrelizumab Treatment.Diagnostics (Basel, Switzerland) · 2026Article
- The Retinal Age Gap as a Marker of Accelerated Aging in the Early Course of Schizophrenia.Schizophrenia bulletin · 2026Article
- Ensemble learning-based method for multiple sclerosis screening from retinal OCT images.Medical & biological engineering & computing · 2025Article
- Structural and Functional Assessment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes Without History of Optic Neuropathy.Journal of clinical medicine · 2025Article
- Optical coherence tomography and angiography reveal early retinal alterations in pediatric-onset multiple sclerosis.European journal of pediatrics · 2025Article
- Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study.Therapeutic advances in neurological disorders · 2025Article
- Diagnostic Value of Inter-Eye Difference Metrics on OCT for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Imaging the optic nerve with optical coherence tomography.Eye (London, England) · 2024Review
- Correlation of Visual System Biomarkers With Motor Deficits in Experimental Autoimmune Encephalomyelitis-Optic Neuritis.Translational vision science & technology · 2024Article
- From progression to progress: The future of multiple sclerosis.Journal of central nervous system disease · 2024Article
- Visual outcome measures in clinical trials of remyelinating drugs.BMJ neurology open · 2024Review
- Optical coherence tomography with voxel-based morphometry: a new tool to unveil focal retinal neurodegeneration in multiple sclerosis.Brain communications · 2024Article
- Topographical Correlation between Structural and Functional Impairment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes with a History of Optic Neuropathy.Journal of clinical medicine · 2023Article
- Retinal Neurodegeneration as a Potential Biomarker of Accelerated Aging in Schizophrenia Spectrum Disorders.Schizophrenia bulletin · 2023Article
- Article
- Serum Neurofilaments and OCT Metrics Predict EDSS-Plus Score Progression in Early Relapse-Remitting Multiple Sclerosis.Biomedicines · 2023Article
- Peripapillary hyperreflective ovoid mass-like structures: Multimodal imaging-A review.Clinical & experimental ophthalmology · 2023Review
- Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis.Journal of neurology · 2022Article
- Schizophrenia in Translation: Why the Eye?Schizophrenia bulletin · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a progressive neurological disorder characterized by both inflammatory and degenerative components that affect genetically susceptible individuals. Currently, the cause of MS remains unclear, and there is no known cure. Commonly used therapies tend to target inflammatory aspects of MS, but may not halt disease progression, which may be governed by the slow, subclinical accumulation of injury to neuroaxonal structures in the central nervous system (CNS). A recognized challenge in the field of MS relates to the need for better methods of detecting, quantifying, and ameliorating the effects of subclinical disease. Simply stated, better biomarkers are required. To this end, optical coherence tomography (OCT) provides highly reliable, reproducible measures of axonal damage and neuronal loss in MS patients. OCT-detected decrements in retinal nerve fiber layer thickness and ganglion-cell layer-inner plexiform layer thickness, which represent markers of axonal damage and neuronal injury, respectively, have been shown to correlate with worse visual outcomes, increased clinical disability, and magnetic resonance imaging-measured burden of disease in MS patients. Recent reports have also suggested that OCT-measured microcystic macular edema and associated thickening of the retinal inner nuclear layer represent markers of active CNS inflammatory activity. Using the visual system as a putative clinical model in MS, OCT measures of neuroaxonal structure can be correlated with functional outcomes to help us elucidate mechanisms of CNS injury and repair. In this review, we evaluate evidence from the published literature and ongoing clinical trials that support the emerging role of OCT in diagnosing, staging, and determining response to therapy in MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.